ClinicalTrials.Veeva

Menu

Research for Individualized Therapeutics in Rare Genetic Disease

Mayo Clinic logo

Mayo Clinic

Status

Invitation-only

Conditions

Undiagnosed Diseases
Rare Genetic Disease

Treatments

Other: Individualized drug matching per genetic disease

Study type

Observational

Funder types

Other

Identifiers

NCT05236595
21-006562

Details and patient eligibility

About

The purpose of this research study is to identify individuals that have a rare genetic disease without an adequate therapeutic strategy that might be treatable with drug developed to target the disease-causing genetic alteration.

Enrollment

50 estimated patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Has Mayo Clinic or other medical health system ID, or another unique identifier.
  • Able to provide informed consent.
  • Individual must have evidence of a genetic disorder as determined by a provider or genetic counselor with causative or likely causative genetic variants identified by molecular testing.
  • Genetic variants must be hypothesized to be targetable using antisense oligonucleotide drugs (such as: knockdown gain of function alterations, increase protein production for reduced function alterations, or modulate mRNA splicing to correct abnormal splicing, promote normal splicing, or return reading frame to an out-of-frame transcript to restore function, etc.) based on current acceptable understanding of ASO mechanisms of action and tissue/organ targeting efficiency.
  • Biological family member of an enrolled individual.
  • Would be able to travel to a Mayo Clinic site for ongoing treatment should a therapeutic be developed.
  • Treatment at the individual's current disease state would likely provide benefit based on current clinical data and understanding of the progression of the disease.

-Or-

  • Biological family member of an enrolled individual
  • Able to provide informed consent or has a LAR available to provide informed consent

Exclusion Criteria

  • Individuals who have situations that would limit compliance with the study requirements.
  • Institutionalized (i.e. Federal Medical Prison).

Trial design

50 participants in 1 patient group

Rare genetic disease individualized drug development screening candidate
Description:
Patients with targetable disease-causing genetic alterations will be evaluated on a case by case basis. The research study will utilize biospecimens to determine if an individualized therapeutic may be developed as a possible treatment option. If an individualized therapeutic drug can be developed, a future IND FDA application (n=1) will be filed.
Treatment:
Other: Individualized drug matching per genetic disease

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems